- call +1-201-465-4211
- email sales@marketsandresearch.biz
- Call +1-201-465-4211
- Email: sales@marketsandresearch.biz
According to our latest study, the global Circulating Tumor DNA Diagnostics market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
This report is a detailed and comprehensive analysis for global Circulating Tumor DNA Diagnostics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Circulating Tumor DNA Diagnostics market size and forecasts, in consumption value ($ Million), 2018-2029
Global Circulating Tumor DNA Diagnostics market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Circulating Tumor DNA Diagnostics market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Circulating Tumor DNA Diagnostics market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Circulating Tumor DNA Diagnostics
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Circulating Tumor DNA Diagnostics market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Grail, Inc., Guardant Health, Inc., Biodesix, Inc., Exosome Diagnostics and Freenome Inc., etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market segmentation
Circulating Tumor DNA Diagnostics market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Test Kits
Reagents
Market segment by Application
Hospitals
Diagnostics Laboratories
Research Laboratories
Academic Research Institutes
Market segment by players, this report covers
Grail, Inc.
Guardant Health, Inc.
Biodesix, Inc.
Exosome Diagnostics
Freenome Inc.
LungLife AI, Inc.
Inivata Ltd.
Personal Genome Diagnostics, Inc.
CellMax Life
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Circulating Tumor DNA Diagnostics product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Circulating Tumor DNA Diagnostics, with revenue, gross margin and global market share of Circulating Tumor DNA Diagnostics from 2018 to 2023.
Chapter 3, the Circulating Tumor DNA Diagnostics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Circulating Tumor DNA Diagnostics market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Circulating Tumor DNA Diagnostics.
Chapter 13, to describe Circulating Tumor DNA Diagnostics research findings and conclusion.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Product Overview and Scope of Circulating Tumor DNA Diagnostics
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Circulating Tumor DNA Diagnostics by Type
1.3.1 Overview: Global Circulating Tumor DNA Diagnostics Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Circulating Tumor DNA Diagnostics Consumption Value Market Share by Type in 2022
1.3.3 Test Kits
1.3.4 Reagents
1.4 Global Circulating Tumor DNA Diagnostics Market by Application
1.4.1 Overview: Global Circulating Tumor DNA Diagnostics Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospitals
1.4.3 Diagnostics Laboratories
1.4.4 Research Laboratories
1.4.5 Academic Research Institutes
1.5 Global Circulating Tumor DNA Diagnostics Market Size & Forecast
1.6 Global Circulating Tumor DNA Diagnostics Market Size and Forecast by Region
1.6.1 Global Circulating Tumor DNA Diagnostics Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Circulating Tumor DNA Diagnostics Market Size by Region, (2018-2029)
1.6.3 North America Circulating Tumor DNA Diagnostics Market Size and Prospect (2018-2029)
1.6.4 Europe Circulating Tumor DNA Diagnostics Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Circulating Tumor DNA Diagnostics Market Size and Prospect (2018-2029)
1.6.6 South America Circulating Tumor DNA Diagnostics Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Circulating Tumor DNA Diagnostics Market Size and Prospect (2018-2029)
2 Company Profiles
2.1 Grail, Inc.
2.1.1 Grail, Inc. Details
2.1.2 Grail, Inc. Major Business
2.1.3 Grail, Inc. Circulating Tumor DNA Diagnostics Product and Solutions
2.1.4 Grail, Inc. Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Grail, Inc. Recent Developments and Future Plans
2.2 Guardant Health, Inc.
2.2.1 Guardant Health, Inc. Details
2.2.2 Guardant Health, Inc. Major Business
2.2.3 Guardant Health, Inc. Circulating Tumor DNA Diagnostics Product and Solutions
2.2.4 Guardant Health, Inc. Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Guardant Health, Inc. Recent Developments and Future Plans
2.3 Biodesix, Inc.
2.3.1 Biodesix, Inc. Details
2.3.2 Biodesix, Inc. Major Business
2.3.3 Biodesix, Inc. Circulating Tumor DNA Diagnostics Product and Solutions
2.3.4 Biodesix, Inc. Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Biodesix, Inc. Recent Developments and Future Plans
2.4 Exosome Diagnostics
2.4.1 Exosome Diagnostics Details
2.4.2 Exosome Diagnostics Major Business
2.4.3 Exosome Diagnostics Circulating Tumor DNA Diagnostics Product and Solutions
2.4.4 Exosome Diagnostics Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Exosome Diagnostics Recent Developments and Future Plans
2.5 Freenome Inc.
2.5.1 Freenome Inc. Details
2.5.2 Freenome Inc. Major Business
2.5.3 Freenome Inc. Circulating Tumor DNA Diagnostics Product and Solutions
2.5.4 Freenome Inc. Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Freenome Inc. Recent Developments and Future Plans
2.6 LungLife AI, Inc.
2.6.1 LungLife AI, Inc. Details
2.6.2 LungLife AI, Inc. Major Business
2.6.3 LungLife AI, Inc. Circulating Tumor DNA Diagnostics Product and Solutions
2.6.4 LungLife AI, Inc. Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 LungLife AI, Inc. Recent Developments and Future Plans
2.7 Inivata Ltd.
2.7.1 Inivata Ltd. Details
2.7.2 Inivata Ltd. Major Business
2.7.3 Inivata Ltd. Circulating Tumor DNA Diagnostics Product and Solutions
2.7.4 Inivata Ltd. Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Inivata Ltd. Recent Developments and Future Plans
2.8 Personal Genome Diagnostics, Inc.
2.8.1 Personal Genome Diagnostics, Inc. Details
2.8.2 Personal Genome Diagnostics, Inc. Major Business
2.8.3 Personal Genome Diagnostics, Inc. Circulating Tumor DNA Diagnostics Product and Solutions
2.8.4 Personal Genome Diagnostics, Inc. Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Personal Genome Diagnostics, Inc. Recent Developments and Future Plans
2.9 CellMax Life
2.9.1 CellMax Life Details
2.9.2 CellMax Life Major Business
2.9.3 CellMax Life Circulating Tumor DNA Diagnostics Product and Solutions
2.9.4 CellMax Life Circulating Tumor DNA Diagnostics Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 CellMax Life Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Circulating Tumor DNA Diagnostics Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Circulating Tumor DNA Diagnostics by Company Revenue
3.2.2 Top 3 Circulating Tumor DNA Diagnostics Players Market Share in 2022
3.2.3 Top 6 Circulating Tumor DNA Diagnostics Players Market Share in 2022
3.3 Circulating Tumor DNA Diagnostics Market: Overall Company Footprint Analysis
3.3.1 Circulating Tumor DNA Diagnostics Market: Region Footprint
3.3.2 Circulating Tumor DNA Diagnostics Market: Company Product Type Footprint
3.3.3 Circulating Tumor DNA Diagnostics Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
4.1 Global Circulating Tumor DNA Diagnostics Consumption Value and Market Share by Type (2018-2023)
4.2 Global Circulating Tumor DNA Diagnostics Market Forecast by Type (2024-2029)
5 Market Size Segment by Application
5.1 Global Circulating Tumor DNA Diagnostics Consumption Value Market Share by Application (2018-2023)
5.2 Global Circulating Tumor DNA Diagnostics Market Forecast by Application (2024-2029)
6 North America
6.1 North America Circulating Tumor DNA Diagnostics Consumption Value by Type (2018-2029)
6.2 North America Circulating Tumor DNA Diagnostics Consumption Value by Application (2018-2029)
6.3 North America Circulating Tumor DNA Diagnostics Market Size by Country
6.3.1 North America Circulating Tumor DNA Diagnostics Consumption Value by Country (2018-2029)
6.3.2 United States Circulating Tumor DNA Diagnostics Market Size and Forecast (2018-2029)
6.3.3 Canada Circulating Tumor DNA Diagnostics Market Size and Forecast (2018-2029)
6.3.4 Mexico Circulating Tumor DNA Diagnostics Market Size and Forecast (2018-2029)
7 Europe
7.1 Europe Circulating Tumor DNA Diagnostics Consumption Value by Type (2018-2029)
7.2 Europe Circulating Tumor DNA Diagnostics Consumption Value by Application (2018-2029)
7.3 Europe Circulating Tumor DNA Diagnostics Market Size by Country
7.3.1 Europe Circulating Tumor DNA Diagnostics Consumption Value by Country (2018-2029)
7.3.2 Germany Circulating Tumor DNA Diagnostics Market Size and Forecast (2018-2029)
7.3.3 France Circulating Tumor DNA Diagnostics Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Circulating Tumor DNA Diagnostics Market Size and Forecast (2018-2029)
7.3.5 Russia Circulating Tumor DNA Diagnostics Market Size and Forecast (2018-2029)
7.3.6 Italy Circulating Tumor DNA Diagnostics Market Size and Forecast (2018-2029)
8 Asia-Pacific
8.1 Asia-Pacific Circulating Tumor DNA Diagnostics Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Circulating Tumor DNA Diagnostics Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Circulating Tumor DNA Diagnostics Market Size by Region
8.3.1 Asia-Pacific Circulating Tumor DNA Diagnostics Consumption Value by Region (2018-2029)
8.3.2 China Circulating Tumor DNA Diagnostics Market Size and Forecast (2018-2029)
8.3.3 Japan Circulating Tumor DNA Diagnostics Market Size and Forecast (2018-2029)
8.3.4 South Korea Circulating Tumor DNA Diagnostics Market Size and Forecast (2018-2029)
8.3.5 India Circulating Tumor DNA Diagnostics Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Circulating Tumor DNA Diagnostics Market Size and Forecast (2018-2029)
8.3.7 Australia Circulating Tumor DNA Diagnostics Market Size and Forecast (2018-2029)
9 South America
9.1 South America Circulating Tumor DNA Diagnostics Consumption Value by Type (2018-2029)
9.2 South America Circulating Tumor DNA Diagnostics Consumption Value by Application (2018-2029)
9.3 South America Circulating Tumor DNA Diagnostics Market Size by Country
9.3.1 South America Circulating Tumor DNA Diagnostics Consumption Value by Country (2018-2029)
9.3.2 Brazil Circulating Tumor DNA Diagnostics Market Size and Forecast (2018-2029)
9.3.3 Argentina Circulating Tumor DNA Diagnostics Market Size and Forecast (2018-2029)
10 Middle East & Africa
10.1 Middle East & Africa Circulating Tumor DNA Diagnostics Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Circulating Tumor DNA Diagnostics Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Circulating Tumor DNA Diagnostics Market Size by Country
10.3.1 Middle East & Africa Circulating Tumor DNA Diagnostics Consumption Value by Country (2018-2029)
10.3.2 Turkey Circulating Tumor DNA Diagnostics Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Circulating Tumor DNA Diagnostics Market Size and Forecast (2018-2029)
10.3.4 UAE Circulating Tumor DNA Diagnostics Market Size and Forecast (2018-2029)
11 Market Dynamics
11.1 Circulating Tumor DNA Diagnostics Market Drivers
11.2 Circulating Tumor DNA Diagnostics Market Restraints
11.3 Circulating Tumor DNA Diagnostics Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12 Industry Chain Analysis
12.1 Circulating Tumor DNA Diagnostics Industry Chain
12.2 Circulating Tumor DNA Diagnostics Upstream Analysis
12.3 Circulating Tumor DNA Diagnostics Midstream Analysis
12.4 Circulating Tumor DNA Diagnostics Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
List of Tables
Table 1. Global Circulating Tumor DNA Diagnostics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Circulating Tumor DNA Diagnostics Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Circulating Tumor DNA Diagnostics Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Circulating Tumor DNA Diagnostics Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Grail, Inc. Company Information, Head Office, and Major Competitors
Table 6. Grail, Inc. Major Business
Table 7. Grail, Inc. Circulating Tumor DNA Diagnostics Product and Solutions
Table 8. Grail, Inc. Circulating Tumor DNA Diagnostics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Grail, Inc. Recent Developments and Future Plans
Table 10. Guardant Health, Inc. Company Information, Head Office, and Major Competitors
Table 11. Guardant Health, Inc. Major Business
Table 12. Guardant Health, Inc. Circulating Tumor DNA Diagnostics Product and Solutions
Table 13. Guardant Health, Inc. Circulating Tumor DNA Diagnostics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Guardant Health, Inc. Recent Developments and Future Plans
Table 15. Biodesix, Inc. Company Information, Head Office, and Major Competitors
Table 16. Biodesix, Inc. Major Business
Table 17. Biodesix, Inc. Circulating Tumor DNA Diagnostics Product and Solutions
Table 18. Biodesix, Inc. Circulating Tumor DNA Diagnostics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Biodesix, Inc. Recent Developments and Future Plans
Table 20. Exosome Diagnostics Company Information, Head Office, and Major Competitors
Table 21. Exosome Diagnostics Major Business
Table 22. Exosome Diagnostics Circulating Tumor DNA Diagnostics Product and Solutions
Table 23. Exosome Diagnostics Circulating Tumor DNA Diagnostics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Exosome Diagnostics Recent Developments and Future Plans
Table 25. Freenome Inc. Company Information, Head Office, and Major Competitors
Table 26. Freenome Inc. Major Business
Table 27. Freenome Inc. Circulating Tumor DNA Diagnostics Product and Solutions
Table 28. Freenome Inc. Circulating Tumor DNA Diagnostics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Freenome Inc. Recent Developments and Future Plans
Table 30. LungLife AI, Inc. Company Information, Head Office, and Major Competitors
Table 31. LungLife AI, Inc. Major Business
Table 32. LungLife AI, Inc. Circulating Tumor DNA Diagnostics Product and Solutions
Table 33. LungLife AI, Inc. Circulating Tumor DNA Diagnostics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. LungLife AI, Inc. Recent Developments and Future Plans
Table 35. Inivata Ltd. Company Information, Head Office, and Major Competitors
Table 36. Inivata Ltd. Major Business
Table 37. Inivata Ltd. Circulating Tumor DNA Diagnostics Product and Solutions
Table 38. Inivata Ltd. Circulating Tumor DNA Diagnostics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Inivata Ltd. Recent Developments and Future Plans
Table 40. Personal Genome Diagnostics, Inc. Company Information, Head Office, and Major Competitors
Table 41. Personal Genome Diagnostics, Inc. Major Business
Table 42. Personal Genome Diagnostics, Inc. Circulating Tumor DNA Diagnostics Product and Solutions
Table 43. Personal Genome Diagnostics, Inc. Circulating Tumor DNA Diagnostics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Personal Genome Diagnostics, Inc. Recent Developments and Future Plans
Table 45. CellMax Life Company Information, Head Office, and Major Competitors
Table 46. CellMax Life Major Business
Table 47. CellMax Life Circulating Tumor DNA Diagnostics Product and Solutions
Table 48. CellMax Life Circulating Tumor DNA Diagnostics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. CellMax Life Recent Developments and Future Plans
Table 50. Global Circulating Tumor DNA Diagnostics Revenue (USD Million) by Players (2018-2023)
Table 51. Global Circulating Tumor DNA Diagnostics Revenue Share by Players (2018-2023)
Table 52. Breakdown of Circulating Tumor DNA Diagnostics by Company Type (Tier 1, Tier 2, and Tier 3)
Table 53. Market Position of Players in Circulating Tumor DNA Diagnostics, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 54. Head Office of Key Circulating Tumor DNA Diagnostics Players
Table 55. Circulating Tumor DNA Diagnostics Market: Company Product Type Footprint
Table 56. Circulating Tumor DNA Diagnostics Market: Company Product Application Footprint
Table 57. Circulating Tumor DNA Diagnostics New Market Entrants and Barriers to Market Entry
Table 58. Circulating Tumor DNA Diagnostics Mergers, Acquisition, Agreements, and Collaborations
Table 59. Global Circulating Tumor DNA Diagnostics Consumption Value (USD Million) by Type (2018-2023)
Table 60. Global Circulating Tumor DNA Diagnostics Consumption Value Share by Type (2018-2023)
Table 61. Global Circulating Tumor DNA Diagnostics Consumption Value Forecast by Type (2024-2029)
Table 62. Global Circulating Tumor DNA Diagnostics Consumption Value by Application (2018-2023)
Table 63. Global Circulating Tumor DNA Diagnostics Consumption Value Forecast by Application (2024-2029)
Table 64. North America Circulating Tumor DNA Diagnostics Consumption Value by Type (2018-2023) & (USD Million)
Table 65. North America Circulating Tumor DNA Diagnostics Consumption Value by Type (2024-2029) & (USD Million)
Table 66. North America Circulating Tumor DNA Diagnostics Consumption Value by Application (2018-2023) & (USD Million)
Table 67. North America Circulating Tumor DNA Diagnostics Consumption Value by Application (2024-2029) & (USD Million)
Table 68. North America Circulating Tumor DNA Diagnostics Consumption Value by Country (2018-2023) & (USD Million)
Table 69. North America Circulating Tumor DNA Diagnostics Consumption Value by Country (2024-2029) & (USD Million)
Table 70. Europe Circulating Tumor DNA Diagnostics Consumption Value by Type (2018-2023) & (USD Million)
Table 71. Europe Circulating Tumor DNA Diagnostics Consumption Value by Type (2024-2029) & (USD Million)
Table 72. Europe Circulating Tumor DNA Diagnostics Consumption Value by Application (2018-2023) & (USD Million)
Table 73. Europe Circulating Tumor DNA Diagnostics Consumption Value by Application (2024-2029) & (USD Million)
Table 74. Europe Circulating Tumor DNA Diagnostics Consumption Value by Country (2018-2023) & (USD Million)
Table 75. Europe Circulating Tumor DNA Diagnostics Consumption Value by Country (2024-2029) & (USD Million)
Table 76. Asia-Pacific Circulating Tumor DNA Diagnostics Consumption Value by Type (2018-2023) & (USD Million)
Table 77. Asia-Pacific Circulating Tumor DNA Diagnostics Consumption Value by Type (2024-2029) & (USD Million)
Table 78. Asia-Pacific Circulating Tumor DNA Diagnostics Consumption Value by Application (2018-2023) & (USD Million)
Table 79. Asia-Pacific Circulating Tumor DNA Diagnostics Consumption Value by Application (2024-2029) & (USD Million)
Table 80. Asia-Pacific Circulating Tumor DNA Diagnostics Consumption Value by Region (2018-2023) & (USD Million)
Table 81. Asia-Pacific Circulating Tumor DNA Diagnostics Consumption Value by Region (2024-2029) & (USD Million)
Table 82. South America Circulating Tumor DNA Diagnostics Consumption Value by Type (2018-2023) & (USD Million)
Table 83. South America Circulating Tumor DNA Diagnostics Consumption Value by Type (2024-2029) & (USD Million)
Table 84. South America Circulating Tumor DNA Diagnostics Consumption Value by Application (2018-2023) & (USD Million)
Table 85. South America Circulating Tumor DNA Diagnostics Consumption Value by Application (2024-2029) & (USD Million)
Table 86. South America Circulating Tumor DNA Diagnostics Consumption Value by Country (2018-2023) & (USD Million)
Table 87. South America Circulating Tumor DNA Diagnostics Consumption Value by Country (2024-2029) & (USD Million)
Table 88. Middle East & Africa Circulating Tumor DNA Diagnostics Consumption Value by Type (2018-2023) & (USD Million)
Table 89. Middle East & Africa Circulating Tumor DNA Diagnostics Consumption Value by Type (2024-2029) & (USD Million)
Table 90. Middle East & Africa Circulating Tumor DNA Diagnostics Consumption Value by Application (2018-2023) & (USD Million)
Table 91. Middle East & Africa Circulating Tumor DNA Diagnostics Consumption Value by Application (2024-2029) & (USD Million)
Table 92. Middle East & Africa Circulating Tumor DNA Diagnostics Consumption Value by Country (2018-2023) & (USD Million)
Table 93. Middle East & Africa Circulating Tumor DNA Diagnostics Consumption Value by Country (2024-2029) & (USD Million)
Table 94. Circulating Tumor DNA Diagnostics Raw Material
Table 95. Key Suppliers of Circulating Tumor DNA Diagnostics Raw Materials
List of Figures
Figure 1. Circulating Tumor DNA Diagnostics Picture
Figure 2. Global Circulating Tumor DNA Diagnostics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Circulating Tumor DNA Diagnostics Consumption Value Market Share by Type in 2022
Figure 4. Test Kits
Figure 5. Reagents
Figure 6. Global Circulating Tumor DNA Diagnostics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 7. Circulating Tumor DNA Diagnostics Consumption Value Market Share by Application in 2022
Figure 8. Hospitals Picture
Figure 9. Diagnostics Laboratories Picture
Figure 10. Research Laboratories Picture
Figure 11. Academic Research Institutes Picture
Figure 12. Global Circulating Tumor DNA Diagnostics Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 13. Global Circulating Tumor DNA Diagnostics Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 14. Global Market Circulating Tumor DNA Diagnostics Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 15. Global Circulating Tumor DNA Diagnostics Consumption Value Market Share by Region (2018-2029)
Figure 16. Global Circulating Tumor DNA Diagnostics Consumption Value Market Share by Region in 2022
Figure 17. North America Circulating Tumor DNA Diagnostics Consumption Value (2018-2029) & (USD Million)
Figure 18. Europe Circulating Tumor DNA Diagnostics Consumption Value (2018-2029) & (USD Million)
Figure 19. Asia-Pacific Circulating Tumor DNA Diagnostics Consumption Value (2018-2029) & (USD Million)
Figure 20. South America Circulating Tumor DNA Diagnostics Consumption Value (2018-2029) & (USD Million)
Figure 21. Middle East and Africa Circulating Tumor DNA Diagnostics Consumption Value (2018-2029) & (USD Million)
Figure 22. Global Circulating Tumor DNA Diagnostics Revenue Share by Players in 2022
Figure 23. Circulating Tumor DNA Diagnostics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 24. Global Top 3 Players Circulating Tumor DNA Diagnostics Market Share in 2022
Figure 25. Global Top 6 Players Circulating Tumor DNA Diagnostics Market Share in 2022
Figure 26. Global Circulating Tumor DNA Diagnostics Consumption Value Share by Type (2018-2023)
Figure 27. Global Circulating Tumor DNA Diagnostics Market Share Forecast by Type (2024-2029)
Figure 28. Global Circulating Tumor DNA Diagnostics Consumption Value Share by Application (2018-2023)
Figure 29. Global Circulating Tumor DNA Diagnostics Market Share Forecast by Application (2024-2029)
Figure 30. North America Circulating Tumor DNA Diagnostics Consumption Value Market Share by Type (2018-2029)
Figure 31. North America Circulating Tumor DNA Diagnostics Consumption Value Market Share by Application (2018-2029)
Figure 32. North America Circulating Tumor DNA Diagnostics Consumption Value Market Share by Country (2018-2029)
Figure 33. United States Circulating Tumor DNA Diagnostics Consumption Value (2018-2029) & (USD Million)
Figure 34. Canada Circulating Tumor DNA Diagnostics Consumption Value (2018-2029) & (USD Million)
Figure 35. Mexico Circulating Tumor DNA Diagnostics Consumption Value (2018-2029) & (USD Million)
Figure 36. Europe Circulating Tumor DNA Diagnostics Consumption Value Market Share by Type (2018-2029)
Figure 37. Europe Circulating Tumor DNA Diagnostics Consumption Value Market Share by Application (2018-2029)
Figure 38. Europe Circulating Tumor DNA Diagnostics Consumption Value Market Share by Country (2018-2029)
Figure 39. Germany Circulating Tumor DNA Diagnostics Consumption Value (2018-2029) & (USD Million)
Figure 40. France Circulating Tumor DNA Diagnostics Consumption Value (2018-2029) & (USD Million)
Figure 41. United Kingdom Circulating Tumor DNA Diagnostics Consumption Value (2018-2029) & (USD Million)
Figure 42. Russia Circulating Tumor DNA Diagnostics Consumption Value (2018-2029) & (USD Million)
Figure 43. Italy Circulating Tumor DNA Diagnostics Consumption Value (2018-2029) & (USD Million)
Figure 44. Asia-Pacific Circulating Tumor DNA Diagnostics Consumption Value Market Share by Type (2018-2029)
Figure 45. Asia-Pacific Circulating Tumor DNA Diagnostics Consumption Value Market Share by Application (2018-2029)
Figure 46. Asia-Pacific Circulating Tumor DNA Diagnostics Consumption Value Market Share by Region (2018-2029)
Figure 47. China Circulating Tumor DNA Diagnostics Consumption Value (2018-2029) & (USD Million)
Figure 48. Japan Circulating Tumor DNA Diagnostics Consumption Value (2018-2029) & (USD Million)
Figure 49. South Korea Circulating Tumor DNA Diagnostics Consumption Value (2018-2029) & (USD Million)
Figure 50. India Circulating Tumor DNA Diagnostics Consumption Value (2018-2029) & (USD Million)
Figure 51. Southeast Asia Circulating Tumor DNA Diagnostics Consumption Value (2018-2029) & (USD Million)
Figure 52. Australia Circulating Tumor DNA Diagnostics Consumption Value (2018-2029) & (USD Million)
Figure 53. South America Circulating Tumor DNA Diagnostics Consumption Value Market Share by Type (2018-2029)
Figure 54. South America Circulating Tumor DNA Diagnostics Consumption Value Market Share by Application (2018-2029)
Figure 55. South America Circulating Tumor DNA Diagnostics Consumption Value Market Share by Country (2018-2029)
Figure 56. Brazil Circulating Tumor DNA Diagnostics Consumption Value (2018-2029) & (USD Million)
Figure 57. Argentina Circulating Tumor DNA Diagnostics Consumption Value (2018-2029) & (USD Million)
Figure 58. Middle East and Africa Circulating Tumor DNA Diagnostics Consumption Value Market Share by Type (2018-2029)
Figure 59. Middle East and Africa Circulating Tumor DNA Diagnostics Consumption Value Market Share by Application (2018-2029)
Figure 60. Middle East and Africa Circulating Tumor DNA Diagnostics Consumption Value Market Share by Country (2018-2029)
Figure 61. Turkey Circulating Tumor DNA Diagnostics Consumption Value (2018-2029) & (USD Million)
Figure 62. Saudi Arabia Circulating Tumor DNA Diagnostics Consumption Value (2018-2029) & (USD Million)
Figure 63. UAE Circulating Tumor DNA Diagnostics Consumption Value (2018-2029) & (USD Million)
Figure 64. Circulating Tumor DNA Diagnostics Market Drivers
Figure 65. Circulating Tumor DNA Diagnostics Market Restraints
Figure 66. Circulating Tumor DNA Diagnostics Market Trends
Figure 67. Porters Five Forces Analysis
Figure 68. Manufacturing Cost Structure Analysis of Circulating Tumor DNA Diagnostics in 2022
Figure 69. Manufacturing Process Analysis of Circulating Tumor DNA Diagnostics
Figure 70. Circulating Tumor DNA Diagnostics Industrial Chain
Figure 71. Methodology
Figure 72. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
